These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27659159)

  • 41. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
    Golovenko NIa; Borisiuk IIu
    Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leveraging BCS in Development: A Case Study.
    Hoaglund Hyzer CS; Fadda HM; Rodriguez JO; Aburub A
    Mol Pharm; 2015 Oct; 12(10):3685-90. PubMed ID: 26365521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate.
    Kesisoglou F
    AAPS PharmSciTech; 2014 Feb; 15(1):20-28. PubMed ID: 24022346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
    Fagerholm U
    J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro-in vivo correlation strategy applied to an immediate-release solid oral dosage form with a biopharmaceutical classification system IV compound case study.
    Bredael GM; Bowers N; Boulineau F; Hahn D
    J Pharm Sci; 2014 Jul; 103(7):2125-2130. PubMed ID: 24890761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
    Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
    J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
    Thomsen MK
    Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
    [No Abstract]   [Full Text] [Related]  

  • 51. Raman spectroscopy in pharmaceutical product design.
    Paudel A; Raijada D; Rantanen J
    Adv Drug Deliv Rev; 2015 Jul; 89():3-20. PubMed ID: 25868453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using tolerance intervals for assessment of pharmaceutical quality.
    Dong X; Tsong Y; Shen M; Zhong J
    J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
    Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
    Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms.
    Akers MJ
    Int J Pharm Compd; 2017; 21(1):47-56. PubMed ID: 28346198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 59. Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.
    Chang RK; Mathias N; Hussain MA
    AAPS J; 2017 Sep; 19(5):1348-1358. PubMed ID: 28681160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting biopharmaceutical performance of oral drug candidates - Extending the volume to dissolve applied dose concept.
    Muenster U; Mueck W; van der Mey D; Schlemmer KH; Greschat-Schade S; Haerter M; Pelzetter C; Pruemper C; Verlage J; Göller AH; Ohm A
    Eur J Pharm Biopharm; 2016 May; 102():191-201. PubMed ID: 26955751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.